CAS |
936563-96-1 |
Content |
HPLC≥98% |
Chinese Name |
依鲁替尼 |
English Name |
Ibrutinib |
Synonym |
PCI-32765 |
Unit |
Piece |
Purity |
HPLC≥98% |
Molecular Formula |
C25H24N6O2 |
Molecular Weight |
440.5 |
Appearance |
White to off-white solid |
Storage |
Powder : -20℃, 2 years;In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥5mg/ml |
EC |
EINECS 805-642-2 |
MDL |
MFCD20261150 |
InChIKey |
XYFPWWZEPKGCCK-GOSISDBHSA-N |
InChI |
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1 |
PubChem CID |
24821094 |
SMILES |
C=CC(N1C[C@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O |
Description |
Ibrutinib is a small molecule BTK inhibitor that selectively covalently binds to the cysteine residue (Cys-481) on the active site of BTK, irreversibly inhibits the activity of BTK, thereby inhibiting BCR activation of signaling pathways. |
Target Point |
Btk |
Passage |
Protein Tyrosine Kinase/RTK;Angiogenesis |
IC50 |
IC50: 0.5 nM (Btk) |
Data Literature Source |
[1]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20; 107 (29) :13075-80.
[2]. Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9; 117 (23) :6287-96.
[3]. Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13; 13 (4) :R115.
[4]. Wu H, et al. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Sci Rep. 2017 Mar 28; 7 (1) :466. |
Specification |
10mg 10mM*1mL in DMSO 50mg 100mg |